Keychun Park, Ph.D. - Publications

Affiliations: 
2008 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Mechanical Engineering

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. Journal For Immunotherapy of Cancer. 7: 128. PMID 31097034 DOI: 10.1186/s40425-019-0609-x  0.8
2018 Lee H, Lee HY, Sun JM, Lee SH, Kim Y, Park SE, Ahn JS, Park K, Ahn MJ. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29775809 DOI: 10.1016/j.jtho.2018.04.038  0.8
2018 Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). British Journal of Cancer. PMID 29381690 DOI: 10.1038/bjc.2017.465  0.8
2017 Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. 8: 67526-67537. PMID 28978051 DOI: 10.18632/oncotarget.18728  0.8
2017 Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. PMID 28706130 DOI: 10.18632/oncotarget.18728  0.8
2017 Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer. PMID 28102887 DOI: 10.1002/cncr.30537  0.8
2017 Sun JM, Park K. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Current Opinion in Oncology. PMID 28085680 DOI: 10.1097/CCO.0000000000000350  0.8
2016 Cho WK, Oh D, Ahn YC, Shim YM, Zo JI, Sun JM, Ahn MJ, Park K. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget. PMID 27682879 DOI: 10.18632/oncotarget.12200  0.8
2016 Moon SH, Kim HS, Cho YS, Sun JM, Ahn JS, Park K, Kim BT, Ahn MJ, Lee KH. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. Lung Cancer (Amsterdam, Netherlands). 100: 24-9. PMID 27597277 DOI: 10.1016/j.lungcan.2016.07.025  0.8
2016 Choi JW, Kong DS, Seol HJ, Nam DH, Yoo KH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee JI. Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer. World Neurosurgery. PMID 27565474 DOI: 10.1016/j.wneu.2016.08.046  0.8
2016 Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Medical Oncology (Northwood, London, England). 33: 97. PMID 27447711 DOI: 10.1007/s12032-016-0811-3  0.8
2016 Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer. PMID 27315356 DOI: 10.1002/cncr.30135  0.8
Show low-probability matches.